Orchid Cellmark has several accredited locations worldwide.
At Orchid Cellmark, we're building a company that we believe will be able to take advantage of the emerging trends in the growing global identity DNA testing market. We think that our path to growth is sound and our mission clear: Capitalize on the opportunities of today while developing the vision and strengths to tap the potential of tomorrow, always with a view towards building shareholder value. Our Investor Relations Department is committed to providing comprehensive and useful company information and other services of value to our current and prospective investors. Please contact us with any questions, requests or feedback you may have about our company and our web site.
Orchid Cellmark, Inc. Financial Results Conference Calls
Orchid Cellmark Inc. First Quarter 2009 Financial Results will be announced Thursday, May 7, 2009, at 10:00 AM EDT
View the press release
Listen to the conference call
The webcast will be archived for 90 days.
Thomas A. Bologna, President and Chief Executive Officer of Orchid Cellmark, will be presenting at the 2009 Bank of America Health Care Conference in New York City on Wednesday, May 13, 2008 at 4:00 p.m. EDT. The following is the link to the live webcast of Mr. Bologna's presentation: Watch the Presentation
Contact Information
Corporate Headquarters
Orchid Cellmark Inc.
4390 U.S. Route One
Princeton, NJ 08540
Phone: 609-750-2200
Fax: 609-750-6405
Email: mail@orchid.com
Investor Relations Office
Tom Bologna
Jim Smith
Phone: 609-750-2324
Fax: 609-750-6405
Email: ir@orchid.com
Shareholder
Exchange: Nasdaq National Market
Listed Securities: ORCH Common Stock
Transfer Agent:
American Stock Transfer & Trust
Shareholder Services Department
59 Maiden Lane
New York, NY 10038
Phone: 800-937-5449
Independent Auditors
Grant Thornton LLP
Princeton, NJ
Please note that any opinions, estimates or forecasts regarding our historical or predicted performance made by the analysts at these firms are theirs alone and do not represent opinions, forecasts or predictions of Orchid Cellmark or its management. Orchid Cellmark is providing this listing as a service to its stockholders, and does not by listing these firms imply its endorsement of or concurrence with such information, conclusions or recommendations. Some of these firms may be market-makers in Orchid Cellmark stock and/or hold other long or short positions in the stock, and may provide compensated services to Orchid Cellmark.